Neri A, Fabiani M, Barbui A, Vocale C, Miglietta A, Fazio C
Vaccines (Basel). 2022; 10(5).
PMID: 35632534
PMC: 9144765.
DOI: 10.3390/vaccines10050778.
Viviani S
Vaccines (Basel). 2022; 10(4).
PMID: 35455366
PMC: 9027557.
DOI: 10.3390/vaccines10040617.
Warshawsky T
Can Commun Dis Rep. 2019; 39(ACS-1):1-40.
PMID: 31697281
PMC: 6802440.
DOI: 10.14745/ccdr.v39i00a01.
Can Commun Dis Rep. 2019; 36(Suppl 2):1-35.
PMID: 31680692
PMC: 6798877.
DOI: 10.14745/ccdr.v36i00as2.
Mieszala M, Jennings H, Drab M, Gamian A
Arch Immunol Ther Exp (Warsz). 2019; 67(4):237-248.
PMID: 31030218
PMC: 6597602.
DOI: 10.1007/s00005-019-00542-9.
Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine.
Fuery A, Richmond P, Currie A
PLoS One. 2015; 10(7):e0133126.
PMID: 26191794
PMC: 4507978.
DOI: 10.1371/journal.pone.0133126.
Surveillance of adverse events following immunization with meningococcal group C conjugate vaccine: Tuscany, 2005-2012.
Levi M, Donzellini M, Varone O, Sala A, Bechini A, Boccalini S
J Prev Med Hyg. 2015; 55(4):145-51.
PMID: 26137788
PMC: 4718312.
Synthesis and immunological study of α-2,9-oligosialic acid conjugates as anti-group C meningitis vaccines.
Liao G, Zhou Z, Guo Z
Chem Commun (Camb). 2015; 51(47):9647-50.
PMID: 25973942
PMC: 4526240.
DOI: 10.1039/c5cc01794g.
Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.
Vasquez A, Manzo R, Soto D, Barrientos M, Maldonado A, Mosqueira M
Hum Vaccin Immunother. 2015; 11(3):776-88.
PMID: 25750999
PMC: 4514328.
DOI: 10.1080/21645515.2015.1011011.
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
Levy J, Licini L, Haelterman E, Moris P, Lestrate P, Damaso S
Hum Vaccin Immunother. 2015; 11(3):620-31.
PMID: 25715157
PMC: 4514337.
DOI: 10.1080/21645515.2015.1011021.
Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.
Khatami A, Clutterbuck E, Thompson A, McKenna J, Pace D, Birks J
PLoS One. 2014; 9(7):e101672.
PMID: 25020050
PMC: 4096514.
DOI: 10.1371/journal.pone.0101672.
Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers.
Stoof S, van der Klis F, van Rooijen D, Knol M, Sanders E, Berbers G
PLoS One. 2014; 9(6):e100651.
PMID: 24963638
PMC: 4070982.
DOI: 10.1371/journal.pone.0100651.
Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.
Pascucci M, Di Gregori V, Frasca G, Rucci P, Finarelli A, Moschella L
Hum Vaccin Immunother. 2014; 10(3):671-6.
PMID: 24384537
PMC: 4130270.
DOI: 10.4161/hv.27597.
First evidence for a covalent linkage between enterobacterial common antigen and lipopolysaccharide in Shigella sonnei phase II ECALPS.
Gozdziewicz T, Lugowski C, Lukasiewicz J
J Biol Chem. 2013; 289(5):2745-54.
PMID: 24324266
PMC: 3908407.
DOI: 10.1074/jbc.M113.512749.
Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
Micoli F, Romano M, Tontini M, Cappelletti E, Gavini M, Proietti D
Proc Natl Acad Sci U S A. 2013; 110(47):19077-82.
PMID: 24191022
PMC: 3839747.
DOI: 10.1073/pnas.1314476110.
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.
E Pichichero M
Hum Vaccin Immunother. 2013; 9(12):2505-23.
PMID: 23955057
PMC: 4162048.
DOI: 10.4161/hv.26109.
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
Knuf M, Romain O, Kindler K, Walther U, Tran P, Pankow-Culot H
Eur J Pediatr. 2013; 172(5):601-12.
PMID: 23307281
PMC: 3631514.
DOI: 10.1007/s00431-012-1924-0.
Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller J
Hum Vaccin Immunother. 2012; 8(12):1892-903.
PMID: 23032159
PMC: 3656082.
DOI: 10.4161/hv.22166.
Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.
Knuf M, Baine Y, Bianco V, Boutriau D, Miller J
Hum Vaccin Immunother. 2012; 8(7):866-72.
PMID: 22485049
PMC: 3495722.
DOI: 10.4161/hv.20229.
Meningococcal conjugate vaccines: optimizing global impact.
Terranella A, Cohn A, Clark T
Infect Drug Resist. 2011; 4:161-9.
PMID: 22114508
PMC: 3215346.
DOI: 10.2147/IDR.S21545.